Abbott and AstraZeneca announced today that they have entered into an agreement for AstraZeneca to co-promote Abbott's TRILIPIX (fenofibric acid), a medication for use alone or in combination with a statin to treat certain lipid disorders. Under the terms of the agreement, AstraZeneca will obtain the non-exclusive right to co-promote TRILIPIX alongside Abbott in the United States, excluding Puerto Rico. Specific financial terms were not disclosed.

Similar posts: order viagra online